Replies to post #5792 on Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Think BIG Like Chris & Mark (CEO & CSO):

Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56% Outperforming USFDA Approved Treatments Nintedanib and Pirfenidone

NP-120 is a drug currently used for neurological indications in Japan, and was originally developed by a global top 10 pharmaceutical company. NP-121 is a repositioned drug that has undergone extensive Phase II and III testing.

http://www.globenewswire.com/news-release/2019/07/03/1877782/0/en/Algernon-Pharmaceuticals-NP-120-Reduced-Fibrosis-in-an-Idiopathic-Pulmonary-Fibrosis-Study-by-56-Outperforming-USFDA-Approved-Treatments-Nintedanib-and-Pirfenidone.html


^All of the Top 10 have Year Over Year Revenue Increases

Keeping in mind, AbbVie just bought Allergan (AGN) for $63 Billion USD. Allergan is not even in the Top 10 rankings and Abbvie currently sits at 7th Largest Pharma out the bunch. We're in other galaxy territory in terms of buyout potential.

Just facts,

/////AMG